![]() Patients will be randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo, and evaluated over a 48-week treatment period. In June 2022, Fulcrum Therapeutics initiated a randomized, double- blind, placebo-controlled, multi-national trial to evaluate the efficacy and safety of losmapimod for the treatment of FSHD.Facioscapulohumeral Muscular Dystrophy Emerging therapies such as -AOC 1020, Losmapimod, MC-DX4, DYNE-301, and others are expected to have a significant impact on the Facioscapulohumeral Muscular Dystrophy market in the coming years.Facioscapulohumeral Muscular Dystrophy Key players such as – miRecule, Fulcrum Therapeutics, Dyne Therapeutics, Avidity Biosciences, and others, are developing therapies for the Facioscapulohumeral Muscular Dystrophy treatment Companies across the globe are diligently working toward developing novel Facioscapulohumeral Muscular Dystrophy treatment therapies with a considerable amount of success over the years.Some of the key takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report: Other arm and leg muscles are frequently eventually affected in the course of the disease. Hamstring and trunk muscles are affected early on but are less well recognized. DelveInsight’s ‘Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Facioscapulohumeral Muscular Dystrophy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Facioscapulohumeral Muscular Dystrophy pipeline domain.įacioscapulohumeral Muscular Dystrophy Overviewįacioscapulohumeral muscular dystrophy is a genetic muscle disorder in which the muscles of the face, shoulder blades, and upper arms are among the most affected.
0 Comments
Leave a Reply. |